Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Bank of Nova Scotia — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Bank of Nova Scotia trades at $84.88 (market cap $105.63B). The key difference: Bank of Nova Scotia is far larger — about 23.5× ACADIA Pharmaceuticals Inc.'s market cap, and Bank of Nova Scotia pays a 3.83% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | BNS | |
|---|---|---|
Market Cap | $4.49B | $105.63B |
Sector | Health | Financials |
52-Week High | $28.06 | $87.35 |
52-Week Low | $20.06 | $54.50 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 3.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BNS trades at $86.20, up 0.94% today, with strong technical momentum showing bullish moving averages and resistance near $88. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS expected at $1.51, while revenue grew to $37.10B in 2025. Recent news highlights dividend increases and strategic acquisitions like MapleMark Bank, reinforcing growth prospects in global markets.
Outlook remains positive with analyst consensus favoring Buy ratings (52.63%), though valuation multiples like P/E of 17.05 warrant monitoring. Key risks include economic sensitivity and debt levels, but robust cash flow and dividend yield support income-focused investors. Upside depends on execution of growth initiatives and sustained earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
